On May 2, 2022, a biotechnology company by the name of Vaxxinity announced that it received fast track designation from the FDA for its development of a new class of immunotherapeutic vaccines for the treatment of Alzheimer’s.
The vaccine known as UB-311 is an intramuscular injection intended to target toxic forms of accumulated amyloid plaque in the brain by using the body’s immune system to destroy the plaque. The accumulation of beta amyloid is what causes the nerve cell damage and eventual cell death that leads to brain shrinkage, the key factor of Alzheimer’s disease. Previous trials have shown that UB-311 to be well tolerated in patients with mild to moderate Alzheimer’s disease.
This fast track designation will allow for frequent engagement with the FDA to discuss plans for development and design of clinical trials. With as many as 5.8 million Americans living with dementia, as lasted reported by the CDC in 2020, this could be an incredible step in the direction of Alzheimer’s treatment and prevention.
For more information regarding the vaccine and information found here please visit the following websites:https://www.alzforum.org/therapeutics/ub-311 https://www.globenewswire.com/news-release/2022/05/02/2433453/0/en/Vaxxinity-Receives-FDAFast-Track-Designation-for-UB-311-for-Treatment-of-Alzheimer-s-Disease.html https://www.precisionvaccinations.com/vaccines/ub-311-alzheimersvaccine#:~:text=UB%2D311%20is%20administered%20as%20an%20intramuscular%20injection. https://www.cdc.gov/aging/aginginfo/alzheimers.htm#:~:text=In%202020%2C%20as%20many%20as,were%20living%20with%20Alzheimer’s%20disease.&text=Younger%20people%20may%20get%20Alzheimer’s,14%20million%20people%20by%202060.